Comparative Pharmacology
Head-to-head clinical analysis: JYLAMVO versus VYLOY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JYLAMVO versus VYLOY.
JYLAMVO vs VYLOY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JYLAMVO (methotrexate) is a folate analog that inhibits dihydrofolate reductase (DHFR), thereby disrupting DNA synthesis and repair. It also inhibits purine and thymidylate synthesis, leading to immunosuppressive and antineoplastic effects.
VYLOY (zolbetuximab-clzb) is a chimeric IgG1 monoclonal antibody that binds to claudin 18.2 (CLDN18.2), a tight junction protein expressed on the surface of gastric cancer cells. Binding induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to tumor cell death.
Oral: 30 mg twice daily for adults with relapsed or refractory acute myeloid leukemia (AML) as a monotherapy.
VYLOY (zolbetuximab-clzb) is administered intravenously at a dose of 800 mg every 2 weeks following a loading dose of 1200 mg on day 1 of cycle 1.
None Documented
None Documented
Terminal elimination half-life is 12-16 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Approximately 2.2 hours (terminal elimination half-life); clinical context: supports twice-weekly dosing schedule.
Primarily renal elimination as unchanged drug (approximately 70-80%) with minor biliary/fecal excretion (20-30%).
Primarily hepatobiliary excretion into feces; minimal renal elimination (<1% unchanged in urine).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent